May 20, 2021
Heart problems are usually not sudden, out-of-nowhere events. Sometimes, an issue with heart disease goes undiagnosed or ignored until it gets bad enough to cause heart failure or a heart attack. It’s important to know what your heart is telling you if you experience a change in your normal condition, including breathing changes, pain and fatigue.
Among those who have recovered from COVID-19, however, physicians are seeing some patients develop new and sudden heart conditions. Because COVID-19 is considered a respiratory infection, one of the more serious and telltale COVID-19 symptoms is a shortness of breath, which can leave the heart with an inadequate level of oxygen. A low level of oxygen can cause blood cells to inflame, possibly creating blood clots and potentially leading to a heart attack and strain on the heart.
New Approach to Heart Failure Targets Myocardial Fibrosis
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Even One Drink Doubles Risk for AF Within 4 Hours
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Renal Denervation for Resistant Hypertension Is Not Back on Track
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
EXPLORER-HCM Trial finds substantial health status improvements with mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
Share Article
Saint Luke s Mid America Heart Institute shared trial findings at American College of Cardiology’s 2021 Scientific Session
The benefits observed were amongst the largest we have ever seen from a medication to improve the symptoms, function and quality of life of patients with heart failure. KANSAS CITY, Mo. (PRWEB) May 20, 2021 The EXPLORER-HCM (Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy) Randomized Clinical Trial has shown significant improvement in the symptoms, function, and quality of life in patients with obstructive hypertrophic cardiomyopathy (oHCM) with taking mavecamten. This comes following no major advances for treating oHCM in more than 30 years, where the primary goals of treat